Browse the evidence

Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides vasculoprotective and anti-atherosclerotic benefits by stimulating endothelial progenitor cell mobilization, enhancing nitric oxide synthase activity, and suppressing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6).

If you have Type 2 Diabetes or obesity with cardiovascular risk factors, Tirzepatide is not just a weight-loss drug. It actively protects your blood vessels by improving endothelial function and reducing inflammation. The standard protocol starts at a low dose (2.5 mg) once weekly and titrates up to 15 mg based on tolerance and glycemic goals. It is administered via subcutaneous injection alongside lifestyle changes.

Current incretin-based therapies (GLP-1 and GLP-1/GIP agonists) primarily reduce body weight through decreased food intake, but they fail to increase energy expenditure (EE) and often cause a compensatory drop in basal metabolic rate, which hinders sustainable weight loss.

If you are using GLP-1 medications like semaglutide or tirzepatide, expect significant weight loss primarily from eating less, not from burning more calories. Be aware that your body will likely slow down its resting metabolism as you lose weight, which can make maintaining loss difficult. This is a known biological adaptation, not a personal failure. Future treatments may combine appetite suppression with energy expenditure boosting to overcome this.

Hypoglycemia occurs in approximately 9% of GLP-1/GIP RA emergency exposures, a rate higher than previously reported, even in the absence of concomitant hypoglycemic medications.

Be aware that GLP-1 medications can cause low blood sugar, even if you aren't taking insulin. This is more likely if you skip meals, exercise heavily, or take a higher dose. Monitor your blood sugar if you feel shaky, dizzy, or confused, and treat lows with fast-acting carbohydrates.

Bone Mineral Content (BMC) continues to decline during the weight regain phase (6-12 months) even when total body weight and fat mass are increasing.

If you lose a significant amount of weight (5% or more), your bone density may drop. This drop can continue even if you regain some of the weight later. To protect your bones, consider baseline bone density assessments if you are at risk (e.g., postmenopausal women) and ensure adequate calcium and vitamin D intake alongside resistance training.

Short-term overnutrition directly impairs thyroid hormone biosynthesis and peripheral T4-to-T3 conversion, causing hypothyroidism and reduced energy expenditure, despite compensatory thyroidal adaptations.

Obesity can directly damage thyroid function and slow metabolism, creating a vicious cycle. However, this damage is largely reversible with weight loss. Focus on sustainable caloric reduction rather than seeking thyroid fixes alone, as the thyroid dysfunction is a symptom of overnutrition, not the root cause.

Overnutrition reduces whole-body energy expenditure by impairing peripheral T4-to-T3 conversion via decreased D2 activity, rendering obese individuals resistant to T4 therapy.

Obesity impairs your body's ability to convert T4 into active T3, which lowers your metabolism and makes T4 supplements less effective for weight loss. The solution is not more thyroid medication, but weight loss, which restores normal thyroid function.

Off-label use of GLP-1 agonists by healthy athletes for aesthetic or performance purposes raises ethical, legal, and safety concerns, including potential classification as doping and inequality in sports access.

Using GLP-1 agonists off-label for aesthetic or performance reasons is not approved and carries ethical and legal risks. It may be viewed as doping and creates inequality in sports. Athletes should consult regulatory bodies and prioritize approved medical indications over off-label use for performance enhancement.

Genotype-based dietary interventions (low-carb vs. low-fat) do not significantly impact weight loss outcomes, suggesting that genotyping alone is not an effective precision medicine approach for weight loss.

Don't pay for expensive genetic testing to tell you whether to eat low-carb or low-fat. Current high-quality evidence shows that your genotype does not predict whether you will lose more weight on one diet versus the other. Focus on finding a dietary pattern you can adhere to consistently that creates a caloric deficit.

Tirzepatide administration (2.5-15 mg weekly) causes injection-site reactions (ISRs) in 2-8% of patients, presenting as localized erythema, swelling, or pruritus, which are generally mild, self-limiting, and comparable in frequency to other GLP-1 agonists.

Expect mild redness or itching at the injection site in the first few weeks. This is common and usually goes away on its own. Rotate your injection sites (abdomen, thigh, upper arm) and use clean needles to reduce irritation. If you get a rash that spreads or doesn't go away, contact your doctor.

Tirzepatide use is associated with rare but serious hypersensitivity reactions, including anaphylaxis and angioedema, occurring in approximately 1-4% of patients, often linked to anti-drug antibodies but not always causally related.

Watch for signs of a severe allergic reaction, such as swelling of the face/throat, difficulty breathing, or widespread hives. These are rare but serious. If you experience them, seek emergency medical help immediately. Most skin reactions are mild and go away on their own.

Excess and dysfunctional epicardial adipose tissue (EAT) contributes to coronary microvascular dysfunction (CMD) and vasospastic angina (VSA) through pro-inflammatory signaling, oxidative stress, and smooth muscle hyperreactivity.

If you have chest pain with normal arteries (CMD or VSA), reducing epicardial fat through lifestyle or medication may improve symptoms by lowering inflammation and improving blood vessel function.

GLP-1 receptor agonist utilization for obesity has increased significantly and disproportionately among women compared to men, with obesity emerging as a key predictor of use specifically in female patients.

If you are a woman with obesity, you are significantly more likely to be prescribed a GLP-1RA than a man with similar characteristics, particularly after 2021. This utilization gap is driven by stronger associations between obesity and prescription in women. Men should be aware that they may face lower prescription rates and should proactively discuss weight management options with their providers.

Depression is uniquely and significantly associated with increased GLP-1RA utilization in women, suggesting a complex interplay between mental health comorbidities and medication access.

For women, having a diagnosis of depression is linked to a higher likelihood of being prescribed GLP-1RAs. This may reflect targeted prescribing or the complex relationship between mental health and weight management. It highlights the need for sex-sensitive screening and holistic care that addresses both metabolic and psychiatric health.

Maxillomandibular advancement (MMA) surgery achieves the largest and most durable reductions in OSA severity, with efficacy comparable to CPAP.

If you have severe sleep apnea and cannot use CPAP, ask about Maxillomandibular Advancement (MMA) surgery. It is a major surgery but can provide a permanent, CPAP-level reduction in apnea events for the right candidate.

There are confirmed cases of falsified GLP-1 receptor agonists in Brazil, indicating supply chain vulnerabilities.

Counterfeit GLP-1 drugs have been confirmed in Brazil. Patients should obtain medications through regulated channels to avoid falsified products.

The presence of anti-drug antibodies (ADAs) to GLP-1 receptor agonists does not necessarily neutralize their clinical efficacy, although it may increase the risk of hypersensitivity reactions.

If you develop antibodies to your GLP-1 medication, it does not automatically mean it has stopped working for weight loss. However, you may experience more injection site reactions. Discuss these symptoms with your doctor; they may not need to stop the drug unless side effects are severe.

Intensive lifestyle interventions (diet and exercise) alone are insufficient to prevent significant weight regain after discontinuation of incretin-based therapy, although they may modestly attenuate the rebound.

Even if you commit to intense diet and exercise after stopping your weight loss medication, you will likely regain a significant amount of weight. Lifestyle changes are important for your health, but they are not a substitute for the medication's hormonal effects in preventing regain.

GLP-1 and GIP receptor agonists improve hepatic outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), including resolution of MASH and improvement in fibrosis.

GLP-1 therapies can significantly improve liver health in patients with MASH, including resolving the disease and improving fibrosis in many cases. This benefit is partly due to weight loss but also involves direct effects on liver tissue. Early treatment is crucial, as benefits are not seen in advanced cirrhosis. Patients with fatty liver should discuss these options with their doctor.

GLP-1 receptor agonists (GLP-1RAs) cause frequent, dose-dependent gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation, reflux) that typically diminish over time but are a major cause of treatment discontinuation.

If you start a GLP-1 medication, expect digestive issues like nausea or diarrhea in the first few months. These symptoms are very common (affecting half to 60% of users) and are usually dose-dependent. The good news is that they typically get better over time. Starting with a lower dose and increasing slowly can help manage this.

GLP-1RAs are associated with an increased risk of hypoglycemia, particularly when combined with insulin or sulfonylureas, although the risk remains lower than with those agents alone.

If you take a GLP-1 medication along with insulin or sulfonylureas, your risk of low blood sugar (hypoglycemia) increases. However, this risk is still lower than if you were taking insulin or sulfonylureas alone. Monitor your blood sugar as advised by your doctor.

Sarcopenia is driven by anabolic resistance, mitochondrial dysfunction, and chronic inflammation, which decouple muscle mass from muscle function.

Understanding that muscle mass and function are different helps explain why you might look stronger but still feel weak. Treating the underlying inflammation and mitochondrial health is as important as building size.

DPP-4 inhibitors (sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin) are cardiovascularly safe (neutral effect on MACE) but do not significantly reduce cardiovascular events or mortality compared to placebo.

DPP-4 inhibitors (like sitagliptin) are safe for your heart and do not increase the risk of heart attacks or strokes, but they also do not reduce these risks. They are a good option for blood sugar control if you cannot tolerate other drugs, but if you have existing heart disease, doctors usually prefer SGLT-2 inhibitors or GLP-1 agonists because those have proven heart benefits.

Standard diagnostic biomarkers (BNP/NT-proBNP) are less reliable in obese patients with HF due to lower circulating levels caused by increased clearance by adipose tissue, requiring lower cut-off values for diagnosis.

If you are obese and have heart failure symptoms, standard blood tests for heart failure (BNP/NT-proBNP) might show lower levels than expected, even if you have the condition. Doctors should use lower thresholds to diagnose you. Do not assume a 'normal' result means you don't have heart failure if you have symptoms.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with a 19% increased risk of incident atrial fibrillation (AF), with risk escalating as liver disease severity (fibrosis/MASH) increases.

If you have MASLD, you have a significantly higher risk of developing atrial fibrillation, even in early stages. Managing metabolic risk factors (weight, blood sugar, blood pressure) is not just about liver health but is a critical strategy for preventing heart rhythm disorders. Early detection and comprehensive management of MASLD are crucial to mitigate this dual burden.